학술논문
Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study
Document Type
Article
Author
Deodhar, Atul; Gottlieb, Alice B; Boehncke, Wolf-Henning; Dong, Bin; Wang, Yuhua; Zhuang, Yanli; Barchuk, William; Xu, Xie L; Hsia, Elizabeth C; AELION, Jacob; AMARELO-RAMOS, Juan; BALSA, Alejandro; BERGHEA, Florian; BRZEZICKI, Jan; BURNETTE, Michael; FRETZIN, Scott; GARCÍA-CARAZO, Sara; GLADSTEIN, Geoffrey; GOMEZ-REINO, Juan; GOODERHAM, Melinda; GONZÁLEZ-FERNÁNDEZ, Carlos; GOTTLIEB, Alice; GRATACOS, Jordi; HAALAND, Derek; KAMALOVA, Rima; LESZCZYNSKI, Piotr; MARTIN-MOLA, Emilio; MASLYANSKY, Alexey; NAVARRO, Federico; OPRIS, Daniela; PAPP, Kim; PERLAMUTROV, Yuriy; PHILIPP, Sandra; RACEWICZ, Artur; REBROV, Andrey; RELL-BAKALARSKA, Maria; ROSMARIN, David; RUBBERT-ROTH, Andrea; SHERGY, William; SHIRINSKY, Ivan; SONIN, Dmitry; STANISLAV, Marina; SUKHAREV, Alexey; TEMNIKOV, Vadim; VINOGRADOVA, Irina; WAYTZ, Paul; YAKUSHEVICH, Vladimir
Source
The Lancet; June 2018, Vol. 391 Issue: 10136 p2213-2224, 12p
Subject
Language
ISSN
01406736; 1474547X
Abstract
Guselkumab, a human monoclonal antibody that binds to the p19 subunit of interleukin 23, has been approved for the treatment of moderate-to-severe psoriasis. Psoriatic arthritis is a common comorbidity of psoriasis with an umet need for novel treatments. We assessed the efficacy and safety of guselkumab in patients with active psoriatic arthritis.